Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II
Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the product. The 20-valent vaccine includes the 13 serotypes contained in Prevnar 13, the pharma's marketed standard of care vaccine for pneumococcal infection, plus seven additional serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F.
Pfizer Inc. (NYSE:PFE) plans to submit a BLA to FDA for 20vPnC by year end 2020. The vaccine is in three Phase III trials in more than 6,000 adults, including populations of vaccine-naïve adults and adults with prior pneumococcal vaccination...
BCIQ Company Profiles